Transitioning From Lab To Market:An Analysis Of Crispr’S Impact In Revolutionizing The Commercialization Of Genome-Editing Technology
MetadataShow full item record
Since the 1970s, when the era of genome-editing technology began with the introduction of recombinant DNA, a lot ofresearch conductedin labstransitionsinto practical applications that consumers see on the market. The recent discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), a new genome-editing tool, is disrupting genome-editing technology’s path to commercialization. This thesis aims to address the lessons learned from the case study of the FlavrSavr tomato, the first commercialized food product in the U.S., and how those lessons provide insight to the implications of commercially using CRISPR. Then, more broadly, this examination analyzes how awareness of CRISPR’s complexities and the intersection between science and business suggests that commercialization of genome-editing technology needs to be more efficient in the evolving landscape of genome editing. The first task is to understand the role of genome-editing technology in establishing the context in which CRISPR is introduced. The second task involvesdiscussingthe complexities of using CRISPR,focusing on the legal and ethical implications. The third task is to compare the case study of the CRISPR application in sickle-cell anemia to that of antisense technology, an earlier discovered genome-editing technology, application in the Flavr Savr tomato. Lastly, this thesis will evaluate the impact of CRISPR’s developmenton genome-editing technology’s commercialization path and put forth recommendations on how to bridge some of the disconnect between science and business in order to make the commercialization process more efficient.